+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The levonorgestrel intrauterine system in menopausal hormone replacement therapy: Five-year experience



The levonorgestrel intrauterine system in menopausal hormone replacement therapy: Five-year experience



Fertility & Sterility 72(1): 161-163



Objective: To study the long-term effects (5 years) of intrauterine levonorgestrel administration as the progestin part of continuous combined postmenopausal hormone replacement therapy. Design: Prospective clinical study. Setting: Department of obstetrics and gynecology at a central hospital. Patient(s): Twenty postmenopausal women with an intact uterus who had no contraindications to hormone replacement therapy and who wanted to take amenorrhea-inducing hormone replacement therapy to relieve their climacteric symptoms. Intervention(s): A percutaneous E2 gel containing 1.5 mg of E2 was administered daily and a levonorgestrel-releasing intrauterine device was used. Endometrial thickness was measured by vaginal ultrasonography. Endometrial sampling was performed yearly. Main Outcome Measure(s): Clinical compliance, profiles of bleeding, and endometrial thickness and morphology were monitored during 5 years of follow-up. Result(s): Eighteen women completed 1 year of follow-up. Fifteenof these women were willing to continue the study, and 12 of them completed 5 years of follow-up. Spotting was frequent during the first 6 months of the study and declined thereafter. At 1 year, 80% of the women were totally amenorrheic. Of the 15 women who continued the study, 12 were totally amenorrheic and 3 had problems with bleeding. The mean endometrial thickness was ltoreq3 mm during the study. Endometrial morphology showed epithelial atrophy accompanied by decidualization of the stroma in all 12 of the women who were followed up for 5 years. Conclusion(s): Intrauterine administration of progestin through a levonorgestrel-releasing intrauterine device is a good alternative as the progestin part of continuous combined hormone replacement therapy because it effectively opposes the estrogenic effects on the endometrium and induces amenorrhea in most cases.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011522482

Download citation: RISBibTeXText

PMID: 10428167

DOI: 10.1016/s0015-0282(99)00162-4


Related references

Three-year follow-up of the use of a levonorgestrel-releasing intrauterine system in hormone replacement therapy. Acta Obstetricia et Gynecologica Scandinavica 76(2): 145-150, 1997

A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertility & Sterility 76(5): 969-973, 2001

Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. Acta Obstetricia et Gynecologica Scandinavica 76(5): 449-454, 1997

Effect of the levonorgestrel-releasing intrauterine system on the uterine artery pulsatility index in postmenopausal hormone replacement therapy. Ultrasound in Obstetrics and Gynecology 10(5): 350-355, 1998

Intrauterine release of levonorgestrel a new way of adding progestogen in hormone replacement therapy. Obstetrics & Gynecology 79(6): 963-967, 1992

Intrauterine administration of levonorgestrel 5 and 10 mu-g/24 hours in perimenopausal hormone replacement therapy. Acta Obstetricia et Gynecologica Scandinavica 76(5): 449-454, 1997

Peri-menopausal and post-menopausal experience among women with and without hormone replacement therapy. Cadernos de Saude Publica 20(6): 1682-1689, 2004

Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. American Journal of Obstetrics & Gynecology 172(2 PART 1): 562-567, 1995

Percutaneous estradiol gel with an intrauterine levonorgestrel releasing device or natural progesterone in hormone replacement therapy. Maturitas. 26(3): 211-217, 1997

Hormone replacement therapy in the peri-menopausal and post menopausal period: more than half of the women were treated for more than one year. Nederlands Tijdschrift Voor Geneeskunde 147(38): 1853-1855, 2003

Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstetricia Et Gynecologica Scandinavica. 77(7): 758-763,., 1998

Periodontal disease-associated micro-organisms in peri-menopausal and post-menopausal women using or not using hormone replacement therapy. A two-year follow-up study. Bmc Oral Health 10: 10, 2010

The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. Climacteric 18(4): 470-482, 2016

Menopausal experience of users of hormone replacement therapy. Berg, G, Hammar, M International Congress Symposium and Seminar Series, Vol 8; The modern management of the menopause: A perspective for the 21st century 447-451, 1994